Phase 3 Axitinib Data in patients with previously treated advanced renal cell carcinoma

Join study principal investigator Brian I. Rini, MD, for an in-depth discussion on Phase 3 trial results for axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) held at ASCO 2011 on June 6 as part of the Pfizer sponsored program. Dr. Rini presents the results from the first head-to-head study in previously treated advanced rCC.